← Back

Taiko Pharmaceutical Co., Ltd.

Taiko Pharmaceutical Co., Ltd. manufactures and sells over-the-counter (OTC) medicines and quasi-drugs in Japan and internationally. Its OTC brands include SEIROGAN, SEIROGAN TOI A, SEIROGAN Quick C, and PISHUT OD Tablet, while its quasi-drug line includes RAPPA INTESTINAL REGULATOR BF. The company also offers sanitation control products under the Cleverin PR, Cleverin Pro Stick, and Cleverin Pro names, and manufactures and sells wood vinegar-based products. It exports its products, was incorporated in 1946, and is headquartered in Osaka, Japan.

Country
Price · split & dividend adjusted
News & notes moving 4574.JP
Robotics & Physical AI

Terra Drone Passes Defense Equipment Agency's Interceptor Drone Demonstration Test

Terra Drone announced that its domestically produced interceptor drone, the Terra B1, has passed the demonstration test in the Defense Equipment Agency's 'Interceptor Drone Early Acquisition Program.' Additionally, CSSHD is investing in TechMagic, which specializes in cooking robots and business automation solutions. Osaka Titanium plans to raise up to 22 billion yen through the issuance of 7 million new shares and the sale of 1.05 million shares, raising concerns about supply-demand deterioration. Toyo Asano has revised down its consolidated earnings forecast for the fiscal year ending February 2027. Tokio Marine announced a stock split of 1 share into 15 shares and the introduction of a shareholder benefit program. JT received dividends from its consolidated subsidiaries, Morinaga Milk changed its shareholder benefit program and record date, and Sasadoku Printing newly introduced a shareholder benefit program. Seirogan (Daiko Pharmaceutical) applied for a market change to the Tokyo Stock Exchange Standard Market, and Intage Holdings announced the establishment of a share buyback framework and a change of its corporate name.
ウエルスアドバイザー·24dRead more →
4574.JP

Daiko Pharmaceutical resolves to apply for change from Tokyo Stock Exchange Prime to Standard Market

Daiko Pharmaceutical announced on the 25th that its board of directors resolved to apply for a market segment change from the Tokyo Stock Exchange Prime Market to the Standard Market. The company judged that devoting management resources to continuously meet Prime Market criteria is not appropriate from the perspective of long-term management strategy and maximizing shareholder value, and that the Standard Market is more suitable. The company found that as of the end of December 2023 it did not meet the market capitalization of tradable shares, one of the Prime Market listing maintenance criteria, and submitted a plan to achieve compliance in March 2024. As a result of implementing various measures, it confirmed compliance with all criteria as of the end of December 2024. However, as of the end of December 2025 it again breached the same criterion, and in March 2026 it announced that it had entered an improvement period.
Reuters·25dRead more →